An observational study in Whipple Procedures, Pancreatic Cancer and Pancreaticoduodenectomy, sponsored by Evangelismos Hospital. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Evangelismos Hospital · Observational
This prospective observational cohort study examines the energy requirements and nutritional care of patients undergoing total or partial pancreatectomy for pancreatic tumors. Patients undergoing pancreatectomy face major metabolic stress, a high burden of preoperative malnutrition, and frequent exocrine or endocrine insufficiency, yet procedure-specific nutritional guidance is limited. The study measures resting energy expenditure (REE) directly by indirect calorimetry during the early postoperative period and compares it with widely used predictive equations (Harris-Benedict, Schofield) and simplified weight-based targets (25 and 30 kcal/kg) to determine how accurately clinicians can estimate energy needs when calorimetry is unavailable. In the same patients, the study records the route of postoperative nutrition (enteral, parenteral, or combined), energy and protein intake relative to requirements, and diet-related symptoms, and follows postoperative complications, hospital readmission, mortality, and changes in body weight and body mass index through 3-6 months after surgery. By capturing measured energy expenditure and nutritional delivery in one cohort, the study aims to clarify whether adequacy of energy and protein intake, feeding route, or both influence recovery, and to provide primary data for developing individualized nutritional support protocols in this high-risk surgical population.
Background and Rationale Patients undergoing pancreatic resection experience surgical stress, systemic inflammation, and frequent exocrine and endocrine insufficiency that together alter energy metabolism and place them at high risk of nutritional deterioration. Predictive equations and simplified weight-based targets are used routinely to prescribe nutrition when indirect calorimetry is unavailable, but their accuracy in this specific surgical population is poorly characterized, and the degree to which the route and adequacy of postoperative feeding influence recovery has not been examined alongside directly measured energy expenditure in the same patients. This study is designed to address both questions within a single prospective cohort, pairing calorimetry-based measurement of resting energy expenditure with structured documentation of nutritional delivery and clinical outcomes.
Design and Setting The study is a single-center prospective observational cohort study. Consecutive eligible adults undergoing total or partial pancreatectomy for pancreatic tumors are enrolled preoperatively after informed consent. Feeding route is not assigned by the protocol; it is determined case by case by the treating surgical and nutrition support teams according to clinical status and tolerance, and is recorded as an observed exposure. All measurements and data abstraction are performed by trained clinical dietitians and drawn from direct measurement and the medical record.
Indirect Calorimetry Procedure Measured resting energy expenditure (mREE) is determined using a Cosmed Q-NRG+ portable indirect calorimeter. The device is calibrated before each session per the manufacturer's automatic gas-calibration procedure. Measurements are obtained by canopy where feasible, with a face mask used only when a canopy cannot be applied, recording VO₂ and VCO₂. Patients are measured supine, awake, and motionless in the morning after an 8-10 hour fast, at a controlled room temperature of 22-24 °C, following a minimum 20-30 minutes of rest. The first five minutes of each recording are discarded, and steady state is defined as at least five consecutive minutes during which the coefficient of variation in VO₂ and VCO₂ does not exceed 10%. Caffeine and strenuous activity are avoided for at least 12 hours beforehand, and supplemental oxygen is suspended or accounted for where clinically feasible. mREE is derived using the abbreviated Weir equation, mREE = (3.94 × VO₂ + 1.11 × VCO₂) × 1.44, and the respiratory quotient is calculated as VCO₂/VO₂. To reduce the influence of single-timepoint sampling within a dynamic postoperative course, calorimetry is scheduled at more than one time point during the early recovery period where the patient's clinical stability permits, with the exact days recorded.
Estimation of Energy Requirements for Comparison Predicted resting energy expenditure is calculated for each patient using the Harris-Benedict and Schofield equations. Harris-Benedict is applied as: men, 66.47 + 13.75 × weight (kg) + 5.0 × height (cm) - 6.75 × age; women, 665.09 + 9.56 × weight (kg) + 1.84 × height (cm) - 4.67 × age. Schofield is applied by sex and age band. For overweight patients, ideal body weight is used in these equations; for obese patients, corrected weight [ideal body weight + 0.25 × (actual - ideal body weight)] is used. Total energy requirements are additionally estimated from the ESPEN weight-based targets of 25 and 30 kcal/kg of ideal body weight (adjusted using a BMI of 22 kg/m² for overweight and 24.9 kg/m² for obese patients) and compared with mREE adjusted by an activity/stress factor of 1.15. Because the two families of estimates target different quantities - basal/resting expenditure for the equations versus total requirements for the weight-based targets - equation comparisons use raw mREE while weight-based comparisons use mREE × 1.15, and this distinction is retained throughout analysis.
Nutritional Intake and Feeding-Route Documentation For each patient, the route of postoperative nutrition (enteral plus oral, parenteral only, or combined enteral and parenteral) is recorded, together with the formulation used, the daily administered volume, and the delivery rate. Daily energy and protein delivery are quantified and expressed relative to individually calculated requirements to derive an energy deficit and a protein deficit for the early postoperative period. Diet-related symptoms (including diarrhea and abdominal pain) are recorded prospectively. These data support the planned subgroup comparison of outcomes across feeding routes and across strata of energy and protein deficit.
Anthropometry and Body Composition Body weight is measured on a calibrated electronic scale to the nearest 0.1 kg. Height is measured with the patient standing upright, unshod and bare-headed, using the Frankfort horizontal plane for head alignment. BMI is calculated as weight (kg) divided by height squared (m²). Weight and BMI are recorded at the preoperative assessment, at discharge, and at the 3-6 month follow-up, and recent percentage weight change is documented. Because body weight in the early postoperative period is confounded by fluid shifts, third-spacing, and edema, preoperative weight is used as the reference exposure in modeling, and objective body composition assessment (bioelectrical impedance or CT-derived skeletal muscle measurement, where available) is incorporated to distinguish loss of fat mass from loss of lean mass.
Nutritional Risk Screening and Biochemical Markers Preoperative nutritional risk is screened using the Perioperative Nutrition Screen (PONS), which weights recent weight loss, reduced intake or anorexia, low BMI, and the presence of a high-metabolic-risk underlying disease. Serum albumin (as a surrogate marker of visceral protein status) and C-reactive protein (as a marker of systemic inflammation) are recorded as exploratory variables at defined time points around the calorimetry measurement, per the hospital's standard laboratory procedures. Clinical variables including comorbidities, tumor site and surgical procedure, postoperative complications, length of stay, and readmissions are abstracted from the medical record.
Follow-up Schedule Assessments are anchored to the perioperative pathway: a preoperative baseline (anthropometry, screening, biochemistry), early postoperative calorimetry and intake documentation during the index admission, a discharge assessment, and a follow-up contact at 3-6 months after discharge for anthropometry and outcome ascertainment. Complication, readmission, and mortality windows follow the postoperative course as specified in the outcome measures.
Statistical Analysis Plan Analyses will be conducted in Jamovi with two-tailed tests at α = 0.05. Distributional normality is assessed by the Shapiro-Wilk test; normally distributed continuous variables are summarized as mean (SD) and non-normal variables as median (interquartile range), with categorical variables as counts and percentages. Agreement between mREE and each estimation method is evaluated by Bland-Altman analysis, reporting mean bias, 95% limits of agreement, and tests for proportional bias, complemented by accuracy indices (percentage within ±10% and ±20%, mean absolute percentage error, and root mean square error) and by linear regression of estimates against mREE. Determinants of mREE are examined using multiple linear regression with prespecified adjustment sets (unadjusted; age and sex; and additionally CRP and albumin). Changes in weight, BMI, and laboratory markers across time points are analyzed with repeated-measures ANOVA or Friedman's test as appropriate, with pairwise comparisons. Where repeated calorimetry measurements are obtained, longitudinal trajectories are analyzed using linear mixed-effects models to accommodate within-patient correlation and variable measurement timing. Feeding route and deficit strata are compared for complications, readmission, and mortality. The single-center design and anticipated sample size are recognized as constraints on power and generalizability, and subgroup analyses (including by surgical type) are treated as exploratory.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,007 are open to participants now.
This study's planned enrollment of 150 is below the median of 200 across 740 observational studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Evangelismos Hospital is the lead sponsor of 29 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive adult patients admitted for total or partial pancreatectomy - including pancreaticoduodenectomy (Whipple procedure) and distal pancreatectomy - for a pancreatic tumor at the participating surgical center. The cohort reflects the real-world case mix referred for pancreatic resection and therefore includes both malignant tumors and premalignant or benign lesions (such as intraductal papillary mucinous neoplasm and ampullary tumors), spanning the head, body, and tail of the pancreas. Participants are enrolled preoperatively and followed through the early postoperative period and to 3-6 months after discharge. Within this single cohort, the postoperative feeding route (enteral with oral intake, parenteral, or combined) is observed rather than assigned and is analyzed as an exposure of interest.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergoing total or partial pancreatectomy for a pancreatic tumor whose postoperative nutrition is delivered by the enteral route together with oral intake. Feeding route is not assigned by the study; it is determined by the treating surgical and nutrition support teams according to clinical status and tolerance, and recorded as an observed exposure. All participants in this cohort undergo indirect calorimetry and structured documentation of energy and protein intake during the early postoperative period.
Procedure: Pancreatectomy · Diagnostic Test: Indirect calorimetry
Participants undergoing total or partial pancreatectomy for a pancreatic tumor whose postoperative nutrition is delivered exclusively by the parenteral route, as determined clinically by the treating teams. As in the other cohorts, participants undergo indirect calorimetry and documentation of nutritional delivery, complications, and follow-up outcomes.
Procedure: Pancreatectomy · Diagnostic Test: Indirect calorimetry
Participants undergoing total or partial pancreatectomy for a pancreatic tumor who receive combined enteral and parenteral nutrition, as determined clinically by the treating teams. Participants undergo the same calorimetry, intake documentation, and follow-up assessments as the other cohorts.
Procedure: Pancreatectomy · Diagnostic Test: Indirect calorimetry
Total or partial pancreatectomy (including pancreaticoduodenectomy / Whipple procedure and distal pancreatectomy) performed for a pancreatic tumor. This is the qualifying surgical exposure common to all participants. Applies to: Cohort 1, Cohort 2, Cohort 3.
Also known as: Indirect calorimetry
Measurement of resting energy expenditure by indirect calorimetry (Cosmed Q-NRG+), performed under standardized fasting and steady-state conditions during the early postoperative period. This is the reference measurement against which predictive equations and weight-based targets are compared.
Length of Hospital Stay
Total duration of the index hospitalization, in days.
Time frame: From surgery through hospital discharge (up to approximately 30 days).
Agreement Between Measured and Predicted Resting Energy Expenditure
Agreement between mREE and each estimation method (Harris-Benedict, Schofield, 25 kcal/kg, 30 kcal/kg), assessed by Bland-Altman mean bias and 95% limits of agreement, mean absolute percentage error (MAPE), and root mean square error (RMSE). Equations are compared with raw mREE; weight-based targets with activity-adjusted mREE × 1.15.
Time frame: Within 14 days after surgery.
Measured Resting Energy Expenditure (mREE)
Resting energy expenditure measured by indirect calorimetry (Cosmed Q-NRG+) and derived using the abbreviated Weir equation, expressed in kcal/day.
Time frame: Within 14 days after surgery.
. Energy Intake as Percentage of Requirements
Daily energy delivery as a percentage of individually calculated energy requirements, reported overall and by feeding-route group (enteral+oral, parenteral only, combined). Unit of Measure: Percentage of estimated requirements (%)
Time frame: Postoperative days 2, 4, and 8, and up to 30 days (hospital discharge)
Incidence of Postoperative Complications
Proportion of participants with delayed gastric emptying, postoperative pancreatic fistula, or infectious complications, recorded per standard clinical definitions.
Time frame: From surgery through 90 days postoperatively.
All-Cause Mortality
Proportion of participants who died from any cause.
Time frame: At 30, 90, and 180 days after surgery.
Protein Intake as Percentage of Requirements
Daily protein delivery as a percentage of individually calculated protein requirements, reported overall and by feeding-route group (enteral+oral, parenteral only, combined). Unit of Measure: Percentage of estimated requirements (%)
Time frame: Postoperative days 2, 4, and 8, and up to 30 days (hospital discharge)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data underlying published results will be made available to qualified researchers whose proposed use has been approved by an independent review committee. Requests must include a methodologically sound proposal and a signed data-access agreement, and data will be shared only after the necessary approvals from the sponsoring institution and the ethics committee, and only to the extent permitted by the participants' informed consent and applicable data-protection law (including the EU General Data Protection Regulation). Given the single-center design and limited sample size, data will be released in de-identified form with any potentially identifying variables removed or aggregated to minimize re-identification risk.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 6 months after publication of the primary results and ending 36 months after publication.
Access criteria: Access is granted to qualified researchers who submit a written request with a scientifically justified proposal to the corresponding author. Requests are evaluated by the sponsor/institution and require ethics-committee approval and execution of a data-access/data-transfer agreement before any data are released. Data are provided in de-identified form for the approved analysis only and may not be redistributed.
Data sharing details ↗ · www.clinicalnutrition.gr
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evangelismos Hospital